Some publications have reported that SARS-CoV-2 spike RBD proteins induced functional antibody response with acceptable safety profile in non-human primates [11, 12]. This fusion protein was expressed in CHO and formulated with alternative adjuvants with different immune activation including Montanide ISA51, Poly (I:C), and MPLA/Quil-A? as potential vaccine candidate formulations. Continue Reading